CD8A and neoplasm: The authors identified that the combination of sBTLA and an HSP70 vaccine significantly improved the anti-tumor immune response, with combination treatment increasing expression of IL-2, IFN-γ, and CD8+ TILs, and reducing expression of IL-10, TGF-β, and Foxp3 [203].